Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.

Hamidi V, Riggs K, Zhu L, Bermudez Saint Andre K, Westby C, Coverdale S, Dursteler A, Wang H, Miller Iii C, Taegtmeyer H, Gutierrez AD

Metabolic syndrome and related disorders31 Mar 2020Cited by 4 (Europe PMC)

PMID32228379PMCIDPMC7262649DOI10.1089/met.2019.0102PepBankPUB-32228379

Source link PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese adults with prediabetes, exenatide attenuated resting forearm blood flow at 3 hr versus placebo.
In plain wordsIn adults with prediabetes, exenatide reduced resting forearm blood flow at 3 hr compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseResting forearm blood flow at 3 hr
Study
n = 15
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Exenatide attenuated resting FBF at 3 hr (P = 0.003) and 6 hr (P = 0.056) postmeal, compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837901
02HumanRandomized controlled trialEfficacy outcome
In obese adults with prediabetes, the reduction in resting forearm blood flow at 6 hr versus placebo was not significant.
In plain wordsIn adults with prediabetes, resting forearm blood flow at 6 hr did not differ significantly between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeResting forearm blood flow at 6 hr
Study
n = 15
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Exenatide attenuated resting FBF at 3 hr (P = 0.003) and 6 hr (P = 0.056) postmeal, compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837902
03HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, peak forearm blood flow did not differ among exenatide, saxagliptin and placebo groups.
In plain wordsIn adults with prediabetes, peak forearm blood flow was similar with exenatide, saxagliptin and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePeak forearm blood flow
Study
n = 15
Comparator
Saxagliptin and placebo groups
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No group differences were observed for peak FBF, plasma nitrotyrosine, and plasma 8-iso-prostaglandin F2alpha.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837903
04HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, plasma nitrotyrosine did not differ among exenatide, saxagliptin and placebo groups.
In plain wordsIn adults with prediabetes, plasma nitrotyrosine was similar with exenatide, saxagliptin and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePlasma nitrotyrosine
Study
n = 15
Comparator
Saxagliptin and placebo groups
Outcome group
Oxidative stress · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No group differences were observed for peak FBF, plasma nitrotyrosine, and plasma 8-iso-prostaglandin F2alpha.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837904
05HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, plasma 8-iso-prostaglandin F2alpha did not differ among exenatide, saxagliptin and placebo groups.
In plain wordsIn adults with prediabetes, this oxidative stress marker was similar with exenatide, saxagliptin and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePlasma 8-iso-prostaglandin F2alpha
Study
n = 15
Comparator
Saxagliptin and placebo groups
Outcome group
Oxidative stress · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No group differences were observed for peak FBF, plasma nitrotyrosine, and plasma 8-iso-prostaglandin F2alpha.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837905
06HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, exenatide abated the transient triglyceride increase versus placebo.
In plain wordsIn adults with prediabetes, exenatide reduced the temporary postmeal triglyceride rise compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostmeal triglyceride increase
Study
n = 15
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
A transient increase in plasma triglyceride was abated in the exenatide group, when compared to saxagliptin and placebo groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837906
07HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, exenatide abated the transient triglyceride increase versus saxagliptin.
In plain wordsIn adults with prediabetes, exenatide reduced the temporary postmeal triglyceride rise compared with saxagliptin.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostmeal triglyceride increase
Study
n = 15
Comparator
Saxagliptin
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
A transient increase in plasma triglyceride was abated in the exenatide group, when compared to saxagliptin and placebo groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837907
08HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, only the exenatide group showed no significant postmeal insulin increase.
In plain wordsIn adults with prediabetes, insulin did not significantly increase after the meal in the exenatide group.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePlasma insulin increase
Study
n = 15
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Only exenatide group showed no significant upsurge in plasma insulin.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837908
09HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, postmeal glucose decreased with exenatide while it increased with placebo at 2 hr.
In plain wordsIn adults with prediabetes, glucose fell with exenatide but rose with placebo at 2 hr after the meal.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostmeal glucose at 2 hr
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Postmeal glucose increased at 2 hr with placebo and saxagliptin, but simultaneously decreased with exenatide.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837910
10HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes, postmeal glucose decreased with exenatide while it increased with saxagliptin at 2 hr.
In plain wordsIn adults with prediabetes, glucose fell with exenatide but rose with saxagliptin at 2 hr after the meal.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostmeal glucose at 2 hr
Study
n = 15
Comparator
Saxagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Postmeal glucose increased at 2 hr with placebo and saxagliptin, but simultaneously decreased with exenatide.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
Report a problemFND-3222837911

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
In adults with prediabetes, free fatty acids declined in all groups, less markedly with exenatide.
In plain wordsIn adults with prediabetes, free fatty acids fell in all groups, with a smaller fall in the exenatide group.
Peptide
Exenatide (exendin-4)
Outcome
MixedPlasma free fatty acids
Study
n = 15
Comparator
Saxagliptin and placebo groups
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Plasma-free fatty acids significantly declined in all three groups, although less markedly for exenatide.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.
Summary · context
All studies utilized a standardized high-fat meal.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3222837909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT02104739

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

The University of Texas Health Science Center, Houstonn = 21Apr 2014 to Mar 2017

Prediabetes · Obesity

Trial page ClinicalTrials.govUpdated 3 Jul 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.